These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 308998)

  • 1. alpha-difluoromethyl DOPA, a new enzyme-activated irreversible inhibitor of aromatic L-amino acid decarboxylase.
    Palfreyman MG; Danzin C; Bey P; Jung MJ; Ribereau-Gayon G; Aubry M; Vevert JP; Sjoerdsma A
    J Neurochem; 1978 Oct; 31(4):927-32. PubMed ID: 308998
    [No Abstract]   [Full Text] [Related]  

  • 2. Irreversible inhibition of aromatic-L-amino acid decarboxylase by alpha-difluoromethyl-DOPA and metabolism of the inhibitor.
    Ribéreau-Gayon G; Palfreyman MG; Zraïka M; Wagner J; Jung MJ
    Biochem Pharmacol; 1980 Sep; 29(18):2465-9. PubMed ID: 7426053
    [No Abstract]   [Full Text] [Related]  

  • 3. Homologs of dopa, alpha-methyldopa, and dopamine as potential cardiovascular drugs.
    Winn M; Rasmussen R; Minard F; Kyncl J; Plotnikoff N
    J Med Chem; 1975 Apr; 18(4):434-7. PubMed ID: 1079053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the effects of reversible and irreversible inhibitors of aromatic L-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral L-3,4-dihydroxyphenylalanine.
    Huebert ND; Palfreyman MG; Haegele KD
    Drug Metab Dispos; 1983; 11(3):195-200. PubMed ID: 6135575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine metabolism following irreversible inactivation of aromatic amino acid decarboxylase in retina.
    Parkinson D; Baughman R; Masland RH; Rando RR
    J Neurosci; 1981 Nov; 1(11):1205-10. PubMed ID: 6796656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of D,L-alpha-monofluoromethyldopa to distinguish subcellular pools of aromatic amino acid decarboxylase in mouse brain.
    Gardner CR; Richards MH
    Brain Res; 1981 Jul; 216(2):291-8. PubMed ID: 6166354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A method for measuring monoamine turnover in animals using an irreversible inhibitor of aromatic L-amino acid decarboxylase, DL-alpha-mono fluoromethyldopa.
    Palfreyman MG; Zreika M; Arbogast R; Wagner J
    J Pharmacol Methods; 1984 Jul; 11(4):239-51. PubMed ID: 6204167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depression of sympathetic nervous function by DL-alpha-monofluoromethyldopa, an enzyme-activated, irreversible inhibitor of L-aromatic amino acid decarboxylase.
    Fozard JR; Spedding M; Palfreyman MG; Wagner J; Möhring J; Koch-Weser J
    J Cardiovasc Pharmacol; 1980; 2(3):229-45. PubMed ID: 6156322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of radiolabeled monofluoromethyl-Dopa to define the subunit structure of human L-Dopa decarboxylase.
    Maneckjee R; Baylin SB
    Biochemistry; 1983 Dec; 22(26):6058-63. PubMed ID: 6661425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of L-dopa on efflux of cerebral monoamines from synaptosomes.
    Ng KY; Colburn RW; Kopin IJ
    Nature; 1971 Apr; 230(5292):331-2. PubMed ID: 5549411
    [No Abstract]   [Full Text] [Related]  

  • 11. Central decarboxylation and uptake of L-DOPA.
    Andén NE; Engel J; Rubenson A
    Naunyn Schmiedebergs Arch Pharmacol; 1972; 273(1):11-26. PubMed ID: 4260798
    [No Abstract]   [Full Text] [Related]  

  • 12. Further studies on the inhibition of monoamine synthesis by monofluoromethyldopa.
    Bey P; Jung MJ; Koch-Weser J; Palfreyman MG; Sjoerdsma A; Wagner J; Zraïka M
    Br J Pharmacol; 1980 Dec; 70(4):571-6. PubMed ID: 7470730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative penetration of L-dopa and 5-HTP through the brain barrier using dimethyl sulfoxide.
    De la Torre JC
    Experientia; 1970 Oct; 26(10):1117-8. PubMed ID: 5312418
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of monoamine synthesis by irreversible blockade of aromatic aminoacid decarboxylase with alpha-monofluoromethyldopa.
    Jung MJ; Palfreyman MG; Wagner J; Bey P; Ribereau-Gayon G; Zraïka M; Koch-Weser J
    Life Sci; 1979 Mar; 24(11):1037-42. PubMed ID: 449607
    [No Abstract]   [Full Text] [Related]  

  • 15. Block of cerebral actions of L-dopa with methyl receptor substances.
    Cotzias GC; Tang L; Ginos JZ; Nicholson AR; Papavasiliou PS
    Nature; 1971 Jun; 231(5304):533-5. PubMed ID: 4934569
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of 5-hydroxytryptophan on the efflux of noradrenaline from brain slices.
    Feer H; Wirz-Justice A
    Experientia; 1971 Aug; 27(8):885-6. PubMed ID: 5316477
    [No Abstract]   [Full Text] [Related]  

  • 17. Inactivation of 3-(3,4-dihydroxyphenyl)alanine decarboxylase by 2-(fluoromethyl)-3-(3,4-dihydroxyphenyl)alanine.
    Maycock AL; Aster SD; Patchett AA
    Biochemistry; 1980 Feb; 19(4):709-18. PubMed ID: 7356954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake of DOPA and 5-hydroxytryptophan by monoamine-forming neurones in the brain of Helix aspersa.
    Kerkut GA; Sedden CB; Walker RJ
    Comp Biochem Physiol; 1967 Oct; 23(1):159-62. PubMed ID: 5299740
    [No Abstract]   [Full Text] [Related]  

  • 19. (S)-norepinephrine in the tissues of mice and rats given racemic erythro-3,4-dihydroxyphenylserine (DOPS).
    Porter CC; Torchiana ML; Stone CA
    Life Sci I; 1972 Aug; 11(16):787-95. PubMed ID: 4540250
    [No Abstract]   [Full Text] [Related]  

  • 20. L-3,4-dihydroxyphenylalanine-induced of norepinephrine from the rat heart.
    Landsberg L
    Biochem Pharmacol; 1971 Dec; 20(12):3542-7. PubMed ID: 5132898
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.